Nusinersen (Spinraza®)

Nusinersen (Spinraza®) has been available for reimbursement under hospital pricing approval since July 2019. A Managed Access Protocol (MAP) is in place for nusinersen. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of nusinersen under hospital pricing approval.

The prescribing of nusinersen (Spinraza®) under hospital pricing approval is confined to consultant neurologists with experience in the diagnosis and management of Spinal Muscular Atrophy (SMA) in specialist centre(s) in Ireland, who have agreed to the terms of this MAP and have been approved by the HSE.

The approved prescriber must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved prescribers.

A copy of the HSE-Managed Access Protocol for nusinersen (Spinraza®) and the application form for individual reimbursement approval can be found in the Related Files section below.

For further information, please contact

Click here for a Data Snapshot on treatments for SMA.